title: Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis.
abstract: BACKGROUND
  Micafungin is an echinocandin with proven efficacy against a broad range of fungal infections, including those caused by Candida spp.
  
  
  OBJECTIVE
  To evaluate the safety and pharmacokinetics of once-daily 3 mg/kg and 4.5 mg/kg micafungin in children with proven, probable or suspected invasive candidiasis.
  
  
  METHODS
  Micafungin safety and pharmacokinetics were assessed in 2 phase I, open-label, repeat-dose trials. In Study 2101, children aged 2-16 years were grouped by weight to receive 3 mg/kg (≥25 kg) or 4.5 mg/kg (<25 kg) intravenous micafungin for 10-14 days. In Study 2102, children aged 4 months to <2 years received 4.5 mg/kg micafungin. Study protocols were otherwise identical.
  
  
  RESULTS
  Safety was analyzed in 78 and 9 children in Studies 2101 and 2102, respectively. Although adverse events (AEs) were experienced by most children (2101: n=62; 2102: n=9), micafungin-related AEs were less common (2101: n=28; 2102: n=1), and the number of patients discontinuing due to AEs was low (2101: n=4; 2102: n=1). The most common micafungin-related AEs were infusion-associated symptoms, pyrexia and hypomagnesemia (Study 2101), and liver function abnormalities (Study 2102). The micafungin pharmacokinetic profile was similar to that seen in other studies conducted in children, but different than that observed in adults.
  
  
  CONCLUSIONS
  In this small cohort of children, once-daily doses of 3 mg/kg and 4.5 mg/kg micafungin were well tolerated. Pharmacokinetic data will be combined in a population pharmacokinetic analysis to support US dosing recommendations in children.
authors: From the *Duke Clinical Research Institute, Duke University, Durham, NC; †University of California, Los Angeles, CA; ‡Astellas Scientific and Medical Affairs, Inc.; §Astellas Pharma Global Development, Inc., Northbrook, IL; and ¶Children's Hospital of Orange County, Orange, CA.
authors: Daniel K
authors: DK
authors: Benjamin
authors: Jaime G
authors: JG
authors: Deville
authors: Nkechi
authors: N
authors: Azie
authors: Laura
authors: L
authors: Kovanda
authors: Mike
authors: M
authors: Roy
authors: Chunzhang
authors: C
authors: Wu
authors: Antonio
authors: A
authors: Arrieta
mesh_terms: D000293:Adolescent; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D001835:Body Weight; D058365:Candidiasis, Invasive / Q000188:drug therapy* / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D054714:Echinocandins / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007223:Infant; D007677:Kidney Function Tests; D055666:Lipopeptides / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D008111:Liver Function Tests; D008297:Male; D000077551:Micafungin
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077551:Micafungin
references: J Clin Microbiol. 2006 Feb;44(2):324-6
references: 16455878
references: Clin Infect Dis. 2004 Nov 15;39(10):1407-16
references: 15546073
references: J Infect Chemother. 2012 Oct;18(5):741-6
references: 22526385
references: Eur J Drug Metab Pharmacokinet. 2012 Mar;37(1):31-8
references: 21956255
references: Expert Opin Drug Saf. 2011 Mar;10(2):171-83
references: 21306282
references: Antimicrob Agents Chemother. 2005 Aug;49(8):3317-24
references: 16048942
references: Antimicrob Agents Chemother. 2005 Apr;49(4):1331-6
references: 15793107
references: Drugs. 2012 Nov 12;72(16):2141-65
references: 23083111
references: Pediatr Infect Dis J. 2008 Sep;27(9):820-6
references: 18679151
references: Clin Infect Dis. 2009 Mar 1;48(5):503-35
references: 19191635
references: J Clin Microbiol. 2012 Apr;50(4):1199-203
references: 22278842
references: Pediatr Infect Dis J. 2011 Jun;30(6):e97-e102
references: 21378595
references: Antimicrob Agents Chemother. 2007 Oct;51(10):3714-9
references: 17638696
references: Pediatr Infect Dis J. 2012 Dec;31(12):1252-7
references: 22982980
references: Pediatr Infect Dis J. 2012 Jun;31(6):630-2
references: 22301478
references: Pediatr Infect Dis J. 2005 Aug;24(8):736-9
references: 16094234
references: J Clin Pharmacol. 2005 Oct;45(10):1145-52
references: 16172179